Technology
RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107
Published
1 year agoon
By
Strong Use of Composition-of-Matter Coverage: Patent protects the molecular structure of RHB-107, providing market exclusivity beyond method-of-use claims
COVID-19 Therapeutic Use: Includes coverage for treatment of SARS-CoV-2, including wild-type and emerging variants
This patent grant enhances RedHill’s strategic positioning in the global COVID-19 therapeutic space, a market still expected to be worth more than $3 billion in 2025[1], and expands its patent footprint in Asia, a key pharmaceutical market
RHB-107 successfully met the primary endpoint of safety and tolerability, delivering promising reduction in hospitalization efficacy results in a U.S. Phase 2 COVID-19 study[2]. Additional clinical data expected from the externally non-dilutive funded PROTECT study, supported by the U.S. Department of Defense
RHB-107 is a novel, patient-friendly oral, once-daily, host-directed potential broad-acting antiviral expected to act independently of viral spike protein mutations[3]
RALEIGH, N.C. and TEL-AVIV, Israel, April 28, 2025 /PRNewswire/ — RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that the China National Intellectual Property Administration (“CNIPA”) has formally allowed a critical use of composition-of-matter patent for RedHill’s proprietary investigational compound RHB-107 (upamostat), a potential oral treatment for COVID-19 (patent application No. 202311591091.6).
“This newly allowed Chinese patent application is a significant success, enhancing RedHill’s strategic positioning in the global COVID-19 therapeutic space – a market still expected to be worth more than three billion dollars in 2025. It provides broad and robust protection of the use of RHB-107, including its structure in oral formulations targeting SARS-CoV-2 infections, including both wild-type and naturally occurring variants and expanding its patent footprint in Asia, a key pharmaceutical market,” said Guy Goldberg, RedHill’s Chief Business Officer. “It underscores the uniqueness of our antiviral candidate and further strengthens our global intellectual property portfolio as we advance development of a much-needed oral candidate for early, community-based (non-hospitalized) treatment of COVID-19, which still represents a considerable threat to vulnerable patients. As a novel, potentially broad-acting, host-directed antiviral that is expected to act independently of viral spike protein mutations, RHB-107, if approved, could provide a much-needed additional option for use in the early COVID-19 treatment space, alongside Pfizer’s Paxlovid.”
Data from RHB-107’s U.S. Phase 2 study, published in the International Journal of Infectious Diseases, showed a 100% reduction in hospitalization due to COVID-19, with zero patients (0/41) on the RHB-107 arms versus 15% (3/20) hospitalized for COVID-19 on the placebo-controlled arm (nominal p-value=0.0317). The study also showed an approximately 88% reduction in reported new severe COVID-19 symptoms after treatment initiation, with new severe COVID-19 symptoms reported by only 2.4% of the RHB-107 treated group (1/41) compared to 20% (4/20) of patients in the placebo-controlled arm (nominal p-value=0.036). Further post-hoc analysis showed faster recovery periods from severe COVID-19 symptoms with a median of 3 days to recovery with RHB-107 compared to 8 days with placebo. Additional clinical data is expected from the externally non-dilutive funded PROTECT study, supported by the U.S. Department of Defense.
About RHB-107 (upamostat)
RHB-107 is a proprietary, first-in-class, once-daily orally administered investigational antiviral, that targets human serine proteases involved in preparing the spike protein for viral entry into target cells. Because it is host-cell targeted, RHB-107 is expected to also be effective against emerging viral variants with mutations in the spike protein. RHB-107 is well tolerated; in the initial COVID-19 study, among 41 patients only one reported a drug-related adverse reaction (a mild, self-limited, rash).
In addition, RHB-107 inhibits several proteases targeting cancer and inflammatory gastrointestinal disease. RHB-107 has undergone several Phase 1 studies and two Phase 2 studies, demonstrating its clinical safety profile in approximately 200 patients[4].
RedHill acquired the exclusive worldwide rights to RHB-107, excluding China, Hong Kong, Taiwan and Macao, from Germany’s Heidelberg Pharma AG (FSE: HPHA) (formerly WILEX AG) for all indications.
About RedHill Biopharma
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the FDA-approved gastrointestinal drug Talicia, for the treatment of Helicobacter pylori (H. pylori) infection in adults[5], with submission planned for marketing authorization in other territories. RedHill’s key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anticancer, anti-inflammatory and antiviral activity, targeting multiple indications with U.S. Government and academic collaborations for development for radiation and chemical exposure indications such as Gastrointestinal-Acute Radiation Syndrome (GI-ARS), a Phase 2 study in prostate cancer in combination with Bayer’s darolutamide and a Phase 2/3 program for hospitalized COVID-19 patients; (ii) RHB-204, an all-in-one, fixed-dose, orally administered, combination antibiotic therapy with a planned Phase 2 study for Crohn’s disease and Phase 3-stage for pulmonary nontuberculous mycobacterial (NTM) disease; (iii) RHB-104, with positive results from a first Phase 3 study for Crohn’s disease; (iv) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, is in late-stage development as a treatment for non-hospitalized symptomatic COVID-19 and is also targeting multiple other cancer and inflammatory gastrointestinal diseases; and (v) RHB-102, with potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting, positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D. RHB-102 is partnered with Hyloris Pharma (EBR: HYL) for worldwide development and commercialization outside North America.
More information about the Company is available at: www.redhillbio.com / twitter.com/RedHillBio.
Forward Looking Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: market and other conditions; the Company’s ability to regain and maintain compliance with the Nasdaq Capital Market’s listing requirements; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk of current uncertainty regarding U.S. government research and development funding and that the U.S. government is under no obligation to continue to support development of our products and can cease such support at any time; the risk that the CNIPA does not grant the patent in a timely manner or at all; the risk that acceptance onto the RNCP Product Development Pipeline or other governmental and non-governmental development programs will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company’s proposed development plans for its programs; the risk that the Company’s development programs and studies may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional studies may be required; the risk of market and other conditions and that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of any necessary commercial companion diagnostics; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates and Talicia®; (v) the Company’s ability to successfully commercialize and promote Talicia®; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) the Company’s ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (ix) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company’s expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company’s Expanded Access Program; (xiv) competition from other companies and technologies within the Company’s industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 20-F filed with the SEC on April 10, 2025. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.
Category: R&D
[1] https://www.cognitivemarketresearch.com/covid-19-therapeutics-market-report
[2] A randomized, placebo-controlled pilot study of upamostat, a host-directed serine protease inhibitor, for outpatient treatment of COVID-19 Plasse, Terry F et al. International Journal of Infectious Diseases, Volume 128, 148 – 156.
[3] Preliminary data from a recent in vitro study.
[4] https://www.ijidonline.com/article/S1201-9712(22)00638-5/fulltext.
[5] Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of H. pylori infection in adults. For full prescribing information see: www.Talicia.com.
Company contact:
Adi Frish
Chief Corporate & Business Development Officer
RedHill Biopharma
+972-54-6543-112
adi@redhillbio.com
Logo: https://mma.prnewswire.com/media/1334141/RedHill_Biopharma_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/redhill-biopharma-secures-allowance-of-key-chinese-patent-application-for-proprietary-covid-19-treatment-rhb-107-302439596.html
SOURCE RedHill Biopharma Ltd.
You may like
Technology
Stanford, MIT, Carnegie Mellon Lead First-Ever Benchmark of AI Production Capacity Across 50 Global Universities – New 5W AI Communications Report
Published
49 minutes agoon
July 22, 2026By
5W AI Communications ranks universities on six equally weighted dimensions. Tier I set includes Stanford, MIT, Carnegie Mellon, UC Berkeley, Tsinghua, University of Toronto, Peking, and Princeton.
MIAMI, July 22, 2026 /PRNewswire/ — Stanford University, the Massachusetts Institute of Technology, and Carnegie Mellon University lead the first-ever benchmark of AI production capacity across 50 global universities, according to a report released today by 5W AI Communications. The Tier I set of eight universities is completed by the University of California, Berkeley; Tsinghua University; the University of Toronto; Peking University; and Princeton University. The full report is available at www.5wpr.com/research/ai-higher-education-index/.
The 5W AI Higher Education Index 2026 measures where AI is being produced at the university source. Six equally weighted dimensions — Frontier Lab Anchor Density, AI Research Output, AI Curriculum Depth, Founder and Capital Pipeline, Compute and Infrastructure, and modeled AI Citation Share — combine into a composite score on a 0–100 scale.
About the Report
The 5W AI Higher Education Index 2026 was produced by the 5W AI Communications research team over a four-month research window between February and May 2026. All sub-component weightings, three worked sample calculations, five-variant sensitivity checks, and confidence intervals are published in a dedicated methodology chapter.
The report is designed as a benchmark of one specific variable — AI production capacity — rather than a general university ranking. It measures the source-layer capacity of universities to produce frontier AI research, faculty, founders, and technical leadership.
Institutional endowment, undergraduate teaching quality, admissions selectivity, Nobel prize counts, athletic programs, and general research budget are explicitly outside the framework’s scope. Traditional rankings such as QS, Times Higher Education, and Shanghai Rankings measure institutional reputation across all disciplines; the 5W AI Higher Education Index is designed to complement those rankings, not replace them.
The Complete Ranking — 50 Universities
TIER I — Composite ≥ 78
1. Stanford University (USA) — composite 96.0
2. Massachusetts Institute of Technology (USA) — composite 94.7
3. Carnegie Mellon University (USA) — composite 91.3
4. University of California, Berkeley (USA) — composite 88.2
5. Tsinghua University (China) — composite 84.3
6. University of Toronto (Canada) — composite 82.3
7. Peking University (China) — composite 80.3
8. Princeton University (USA) — composite 79.2
TIER II — Composite 70 to 77.9
9. ETH Zurich (Switzerland) — composite 77.5
10. University of Oxford (UK) — composite 75.0
11. University of Cambridge (UK) — composite 74.5
12. University of Washington (USA) — composite 74.0
13. University of Illinois Urbana-Champaign (USA) — composite 72.5
14. Cornell University (USA) — composite 71.5
15. Georgia Tech (USA) — composite 71.0
16. California Institute of Technology (USA) — composite 70.0
TIER III — Composite < 70
17. Harvard University (USA) — composite 69.0
18. Columbia University (USA) — composite 68.0
19. Yale University (USA) — composite 67.0
20. Shanghai Jiao Tong University (China) — composite 66.5
21. National University of Singapore (Singapore) — composite 66.0
22. Hong Kong University of Science and Technology (Hong Kong) — composite 65.5
23. Nanyang Technological University (Singapore) — composite 64.5
24. KAIST (South Korea) — composite 64.0
25. Technion — Israel Institute of Technology (Israel) — composite 63.5
26. University of Michigan (USA) — composite 63.0
27. University of Texas at Austin (USA) — composite 62.5
28. Tel Aviv University (Israel) — composite 62.0
29. University of California, Los Angeles (USA) — composite 61.5
30. EPFL (Switzerland) — composite 61.0
31. University of Chicago (USA) — composite 59.5
32. University of Southern California (USA) — composite 58.5
33. New York University (USA) — composite 58.0
34. Duke University (USA) — composite 56.0
35. Purdue University (USA) — composite 55.0
36. University of Pennsylvania (USA) — composite 54.5
37. Northwestern University (USA) — composite 54.0
38. Vanderbilt University (USA) — composite 53.5
39. University of Wisconsin-Madison (USA) — composite 53.0
40. Technical University of Munich (Germany) — composite 52.5
41. Imperial College London (UK) — composite 52.0
42. Sorbonne / PSL (France) — composite 51.5
43. University of Edinburgh (UK) — composite 51.0
44. University of Waterloo (Canada) — composite 50.5
45. McGill / Mila (Canada) — composite 50.0
46. Seoul National University (South Korea) — composite 48.5
47. University of Tokyo (Japan) — composite 47.0
48. IIT Bombay (India) — composite 45.5
49. IIT Delhi (India) — composite 44.5
50. IISc Bangalore (India) — composite 43.0
Stanford University — The Frontier Anchor
Stanford is the only university scoring in the top three on every one of the six dimensions. The Stanford AI Lab (SAIL) and the Institute for Human-Centered AI (HAI), co-directed by Fei-Fei Li, operate two of the largest concentrations of AI faculty at any US university. Christopher Manning, Andrew Ng, Percy Liang, Chelsea Finn, and Dan Boneh anchor a research bench that produces both foundational research and the technical alumni populating frontier AI companies. Stanford graduates include OpenAI chief executive Sam Altman and Nvidia chief executive Jensen Huang.
Massachusetts Institute of Technology — Institutional Commitment
MIT’s Computer Science and Artificial Intelligence Laboratory (CSAIL) is the largest AI research organization in the world by faculty count. The Stephen A. Schwarzman College of Computing, launched in 2019 with a US$1 billion commitment from Blackstone chairman Stephen Schwarzman, embedded AI into the broader institution’s operating structure. Regina Barzilay, Josh Tenenbaum, and Antonio Torralba anchor the current research bench. President Sally Kornbluth has positioned MIT as a reference institution on AI policy in the current cycle.
Carnegie Mellon University — The Deepest Faculty Bench
Carnegie Mellon operates the largest concentration of AI-active faculty in the world by headcount, spread across the Machine Learning Department, the Language Technologies Institute, the Robotics Institute, and the Human-Computer Interaction Institute. CMU launched the first bachelor’s degree in AI in the United States in 2018, three years ahead of every peer institution. The report finds CMU alumni populate the applied-AI staff of every major frontier lab.
UC Berkeley — The Open-Source Anchor
The Berkeley Artificial Intelligence Research Lab (BAIR), the RISE Lab, and the Sky Computing Lab produce much of the field’s most-cited work of the last five years. Pieter Abbeel, Trevor Darrell, Sergey Levine, and Stuart Russell anchor the current bench. The public-university funding structure creates a specific advantage in open-source AI infrastructure — TensorFlow’s early ties, PyTorch-adjacent research, and the reinforcement-learning frameworks now used across the industry all trace to Berkeley or its adjacent research community.
Tsinghua and Peking — The Chinese Frontier
Tsinghua University ranks fifth on the composite (84.3). Peking University ranks seventh (80.3). Tsinghua’s Institute for Interdisciplinary Information Sciences was founded in 2005 by Andrew Yao, the 2000 Turing Award recipient. Tsinghua faculty and alumni populate DeepSeek’s founding technical team, Zhipu AI’s leadership, and much of the research direction at Alibaba’s DAMO Academy. Peking University’s School of Intelligence Science and Technology anchors the second-largest concentration of AI research output in China. Both universities rank higher on Research and Compute than on Citation Share — a compression the report documents as attributable to English-language bias in Western AI engines.
University of Toronto — Origins of Modern Deep Learning
The University of Toronto, at rank 6 (composite 82.3), is the origin institution of the modern deep-learning revolution. Geoffrey Hinton — the 2018 Turing Award co-recipient with Yoshua Bengio and Yann LeCun — ran the lab that produced the 2012 ImageNet breakthrough. Ilya Sutskever, Alex Krizhevsky, and Ruslan Salakhutdinov emerged from that Toronto lab. Aidan Gomez, co-founder of Cohere, is a Toronto graduate. The Vector Institute, launched in Toronto in 2017 with initial funding of C$150 million, anchors the current ecosystem. The report finds Toronto’s per-capita AI production is the highest in the world outside the Bay Area.
Princeton University — The Ivy in Tier I
Princeton is the only Ivy League institution in Tier I on the composite (79.2). Dario Amodei, Anthropic’s chief executive, and Daniela Amodei, its president, both hold Princeton undergraduate degrees. Sanjeev Arora’s theoretical computer science group and the Center for Statistics and Machine Learning produce sustained frontier-relevant research. Princeton President Christopher L. Eisgruber has become one of the most-cited university leaders on AI policy in the current cycle.
Technion and Tel Aviv University — Israeli Anchor Density
Israel places two universities in the top 30. The Technion — Israel Institute of Technology ranks 25th on the composite (63.5). Tel Aviv University ranks 28th (62.0). Both maintain dense ties to Nvidia’s Israeli R&D operations in Yakum — the semiconductor company’s largest engineering site outside the United States — Intel’s Israeli operations in Kiryat Gat and Haifa, and the alumni pipeline from IDF Unit 8200. The report finds founder-per-capita yield at the Technion rivals Stanford’s.
“AI is being produced inside a small number of universities, and the concentration is structural,” said Ronn Torossian, Founder and Chairman, 5W AI Communications. “This benchmark exists so university leaders, prospective PhD candidates, corporate recruiters, and donors can see where AI is actually being built — with a reproducible methodology anyone can audit and reweight.”
Additional Findings from the Report
Stanford is the only university scoring in the top three on every one of the six dimensions — Frontier Lab Anchor Density, AI Research Output, AI Curriculum Depth, Founder and Capital Pipeline, Compute and Infrastructure, and modeled AI Citation Share.Stanford, MIT, Carnegie Mellon, and UC Berkeley collectively account for an estimated majority of frontier-lab founding technical leadership across OpenAI, Anthropic, Google DeepMind, xAI, and adjacent frontier labs.MIT’s CSAIL is the largest AI research organization in the world by faculty count. Carnegie Mellon operates the largest concentration of AI-active faculty in the world by headcount, distributed across four dedicated schools and institutes.Carnegie Mellon launched the first bachelor’s degree in AI in the United States in 2018 — three years ahead of every peer institution in the report’s universe.The University of Toronto ranks first in the world for per-capita AI production outside the Bay Area, reflecting the founder yield and research productivity of the Hinton lineage and the Vector Institute.China places two universities in Tier I — Tsinghua at rank 5 (composite 84.3) and Peking at rank 7 (composite 80.3). Under language-neutral citation-share normalization, both would rank higher.Princeton is the only Ivy League institution in Tier I, sustained by the Amodei alumni tie to Anthropic and the theoretical CS bench at the Center for Statistics and Machine Learning.Israel places two universities in the top 30 — the Technion at 25 and Tel Aviv University at 28. Founder-per-capita yield at the Technion rivals Stanford’s.The 50-university universe spans 13 countries and regions: the United States (25 universities), China (3), the United Kingdom (4), Canada (3), India (3), Singapore (2), Switzerland (2), South Korea (2), Israel (2), plus one each from France, Germany, Hong Kong, and Japan.The report publishes a five-variant sensitivity check showing how the ranking shifts under founder-weighted, research-weighted, language-neutral citation, and compute-weighted composite formulations.
The Six Dimensions
Frontier Lab Anchor Density. Alumni and current-faculty presence at OpenAI (25%), Anthropic (20%), Google DeepMind (20%), xAI (10%), and others including Mistral, Cohere, DeepSeek, Inflection, and Sierra (25% combined). Sourced from Crunchbase and PitchBook.AI Research Output. Publications at NeurIPS, ICML, and ICLR (40%); ACL and EMNLP (20%); h-index of top 20 AI faculty (25%); AI-related patents (15%). Sourced from CSRankings.org (2018–2025 rolling window) and the Nature Index AI subject data.AI Curriculum Depth. Named AI degree program (30%); dedicated AI school or college (25%); GEO/LLMO in required curriculum (25%); cross-disciplinary integration across CS, business, communications, law, and medicine (20%).Founder and Capital Pipeline. Alumni founder count (40%); AI venture capital raised by alumni-founded companies (30%); AI unicorn count (20%); alumni CEO and senior-technical leadership at frontier labs (10%). Sourced from Crunchbase, PitchBook, and Dealroom.Compute and Infrastructure. On-campus GPU capacity (30%); hyperscaler partnerships across AWS, Azure, GCP, and Oracle (25%); federal AI research funding from NSF, DARPA, DOE, and national equivalents (25%); institutional AI governance maturity (20%).AI Citation Share (Modeled). Modeled share of mentions across 3,600 prompt-engine runs — 60 prompts, five AI engines, three runs per wave, four monthly waves between February and May 2026. Each engine weighted equally at 20% of the dimension.
Methodology
The composite score is the simple unweighted mean of the six dimension scores on a 0–100 scale. Tier boundaries are defined as Tier I (composite ≥ 78), Tier II (composite 70 to 77.9), and Tier III (composite < 70). Tiebreaks are resolved by Dimension 6 (Citation Share). Within each dimension, sub-component weightings are published and applied consistently across all 50 universities. Raw values (paper counts, founder counts, GPU capacity, etc.) are rank-ordered across the universe and mapped to 0–100 with logarithmic smoothing where the raw distribution is heavily skewed. The full methodology chapter is published in the report.
Data Sources and Freeze Dates
Research output is drawn from CSRankings.org (2018–2025 rolling window) and Nature Index AI subject rankings. Faculty h-index data is drawn from institutional bio pages and Google Scholar. Founder-pipeline data is drawn from Crunchbase, PitchBook, and Dealroom. Unicorn counts come from CB Insights. Federal AI funding is drawn from public awards data at NSF, DOE, and DARPA. Hyperscaler partnership data is drawn from Synergy Research and institutional disclosures. All institutional data was frozen as of May 15, 2026. Citation-share modeling ran between February and May 2026 across four monthly waves.
Confidence Intervals and Sensitivity Checks
Composite scores carry an approximate ±2.5 point uncertainty band at the 95% confidence level, driven primarily by Dimension 6 (Citation Share) modeling variance. The report notes that rank differences smaller than five composite points may not be statistically distinguishable, and that tier assignments are more reliable than exact positional rank within a tier. The report publishes a five-variant sensitivity check demonstrating what happens under founder-weighted, research-weighted, language-neutral citation, and compute-weighted composite formulations.
The 60-Prompt Universe
The modeled Citation Share dimension is drawn from 60 prompts distributed across six sub-categories:
General AI universities (10 prompts) — questions about the leading AI universities globally and by regionFaculty and Research (10 prompts) — questions about leading AI researchers, faculty, and research labsStudents and Careers (10 prompts) — questions about undergraduate, graduate, and career-track AI programsFounders and Alumni (10 prompts) — questions about the universities that produced AI founders and CEOsCurriculum and Degrees (10 prompts) — questions about AI courses, ethics programs, and degree structuresIndustry and Funding (10 prompts) — questions about AI research funding, hyperscaler partnerships, and applied specialization
Each prompt is run three times per engine per monthly wave, across four waves — producing 3,600 total prompt-engine executions. Prompt order is randomized within each engine session to control for context-window bias. The full 60-prompt list is published in the report’s methodology appendix.
About 5W AI Communications
5W is the AI Communications Firm, building brand authority across the platforms where decisions now happen — ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews — alongside earned media, digital, and influencer channels. 5W combines public relations, digital marketing, Generative Engine Optimization (GEO), and proprietary AI visibility research to help clients measure and grow their presence in AI-driven buyer research. Founded in 2003, 5W is recognized as a Top U.S. PR Agency by O’Dwyer’s, named Agency of the Year in the American Business Awards®, honored as a 2026 Top Place to Work in Communications by Ragan, and named to Digiday’s WorkLife Employer of the Year list. 5W serves clients across B2C sectors — Beauty & Fashion, Consumer Brands, Entertainment, Food & Beverage, Health & Wellness, Travel & Hospitality, Technology, and Nonprofit — and B2B specialties including Corporate Communications, Reputation Management, Public Affairs, Crisis Communications, and Digital Marketing across Social, Influencer, Paid Media, GEO, and SEO. Learn more at 5wpr.com.
Media Contact
press@5wpr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/stanford-mit-carnegie-mellon-lead-first-ever-benchmark-of-ai-production-capacity-across-50-global-universities–new-5w-ai-communications-report-302832426.html
SOURCE 5W Public Relations
Technology
Pelico signs agreement with Boeing to support C-17 Globemaster III readiness
Published
49 minutes agoon
July 22, 2026By
FARNBOROUGH, England, July 22, 2026 /PRNewswire/ — Pelico today announced a strategic project agreement with Boeing to modernize how C-17A Globemaster III heavy maintenance is planned and executed. Under the agreement, Pelico’s Manufacturing Orchestration Platform will be used as a single, AI-enabled workspace to help reduce depot cycle time, improve fleet availability and make aircraft delivery performance more predictable by connecting supply, engineering, planning and depot workflows and operations.
“Our customers rely on us to help keep their fleets flying safely, and Pelico’s platform will give us a clear, comprehensive view of potential sustainment and support challenges so that we can operate and execute more efficiently, reduce out-of-fleet cycle time, and deliver on our commitments,” said Turbo Sjogren, vice president and general manager of Government Services, Boeing Global Services.
The platform is expected to replace fragmented, spreadsheet-driven processes with a shared, real-time view of material shortages, bottlenecks and maintenance priorities. The agreement builds on an earlier deployment of Pelico’s platform in Boeing Global Services’ commercial spare parts operations that validated its ability to significantly reduce backlog and improve operational efficiency.
“Sustaining aging fleets is one of the most complex problems in aerospace, with sustainment stretching decades” said Tarik Benabdallah, CEO and co-founder of Pelico. “Pelico’s solutions will offer Boeing visibility into complex dependencies across supply, production and repair, so that teams can identify disruptions and coordinate the next action before it becomes a late delivery.”
Boeing and Pelico will use the agreement to assess how similar digital tools could support sustainment operations across additional platforms.
ABOUT PELICO
Pelico is the AI-powered Manufacturing Orchestration Platform for discrete manufacturers in various industries including aerospace, defense, energy managing complex products and multi-plant networks. Pelico closes the gap between what’s planned and what happens on the factory floor, coordinating planning, production, and supply chain teams around one operational reality. Manufacturers use Pelico to reduce shortages, protect on-time delivery, and accelerate turnaround. Backed by General Catalyst, Pelico operates in more than 25 countries. Learn more at pelico.ai.
Media contact: Ina Foalea – Chief of Staff, Pelico — media@pelico.ai — +1 (786) 820-2649
View original content to download multimedia:https://www.prnewswire.com/news-releases/pelico-signs-agreement-with-boeing-to-support-c-17-globemaster-iii-readiness-302832428.html
SOURCE Pelico
Technology
Mission Critical Partners (MCP) Selected to Help Advance Kentucky’s Statewide NG911 Transformation
Published
49 minutes agoon
July 22, 2026By
MCP will provide NG911 procurement and implementation oversight, GIS and cybersecurity support.
STATE COLLEGE, Pa., July 22, 2026 /PRNewswire-PRWeb/ — Mission Critical Partners (MCP) announced that the Kentucky 911 Services Board has selected the firm to support the next phase of its multiyear effort to implement Next Generation 911 (NG911) in every emergency communications center (ECC) statewide. Currently, about 20 percent of the 117 ECCs in the state have transitioned to NG911.
NG911 is a critical step forward in modernizing emergency communications infrastructure, strengthening system resiliency, improving location accuracy, and helping ECCs deliver faster, more reliable service to communities across the commonwealth.
MCP will support the board across several key areas:
Independent third-party oversight — MCP will monitor NG911 procurements and implementations to ensure that deployed systems perform according to technical specifications. They also will monitor system acceptance testing and cutovers to ensure that all elements are performing as contracted before go-live. The goal is to ensure a smooth transition to the new platform without disruptions to emergency communications.
Providing geographic information system (GIS) support — NG911 systems depend on accurate NG911-ready GIS data to route calls and dispatch emergency response to the correct location. MCP will supplement the state’s GIS resources by assisting in the creation and verification of addressing data, as well as the development of ECC and emergency responder boundary polygons, and any other GIS requirements needed to support NG911 operations. This support is particularly important for smaller and rural ECCs that lack dedicated GIS personnel.
Expanding cybersecurity support — MCP will assist the board with various initiatives, including cybersecurity planning and risk management. In addition to addressing any intrinsic vulnerabilities that might exist in NG911 systems, the overarching goal is to strengthen the security posture of all ECCs across the state.
Developing continuity of operations plans (COOPs) — COOPs, disaster recovery documentation, and crisis communications plans are critical elements when an ECC suffers a service-affecting outage. MCP will provide a COOP template that will identify gaps across the state and then work with individual ECCs to address the gaps.
Providing grant and funding guidance — While the board manages its own grant applications, MCP will help state 911 leadership better understand the ECCs’ evolving technological and operational requirements to determine funding priorities.
Updating the board’s strategic roadmap — Given that this is a complex multiyear initiative, MCP will help the board update Kentucky’s strategic roadmap to guide future 911 modernization initiatives and statewide planning efforts.
“The Kentucky 911 Services Board has turned to Mission Critical Partners as its trusted advisor for its NG911 transformation — it’s a role and opportunity that we take very seriously,” said Darrin Reilly, MCP’s president and CEO. “By providing procurement support, implementation oversight, GIS expertise, strategic planning, continuity planning, cybersecurity guidance, and funding-related consultation, we will help the board successfully modernize emergency communications across the state.”
About Mission Critical Partners (MCP)
Mission Critical Partners (MCP) is a leading provider of consulting, technology, and data integration services for public safety, justice, and government organizations. MCP helps its clients advance their missions through modern, interoperable, and data-driven solutions. Learn more at missioncriticalpartners.com
Media Contact
Morgan Sava, Mission Critical Partners, 1 608-658-8858, rscarpino@pipitone.com, https://www.missioncriticalpartners.com/
View original content:https://www.prweb.com/releases/mission-critical-partners-mcp-selected-to-help-advance-kentuckys-statewide-ng911-transformation-302832424.html
SOURCE Mission Critical Partners
Stanford, MIT, Carnegie Mellon Lead First-Ever Benchmark of AI Production Capacity Across 50 Global Universities – New 5W AI Communications Report
Pelico signs agreement with Boeing to support C-17 Globemaster III readiness
Mission Critical Partners (MCP) Selected to Help Advance Kentucky’s Statewide NG911 Transformation
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
New Gooseneck Omni Antennas Offer Enhanced Signals in a Durable Package
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Technology5 days agoGlobal Times: China sends fresh signal on global AI cooperation at WAIC
-
Technology5 days agoe& Successfully Completes Sale of Vodafone Stake, Realizing Cash Proceeds of USD 5.95 Billion
-
Technology5 days agoVizEx launches multilingual platform connecting immigrants with licensed U.S. immigration attorneys
-
Technology5 days agoS&P DOW JONES INDICES AND MSCI ANNOUNCE CONSULTATION ON POTENTIAL CHANGES TO THE GLOBAL INDUSTRY CLASSIFICATION STANDARD (GICS®)
-
Technology4 days agoEmdoor Launches “Ailyn” AI Hub at WAIC 2026: Unifying Intelligence Across Every Device
-
Technology5 days agoMDT Introduces TMR1370 Ultra-Low-Power Magnetic Switch IC Enabling More Than Two Years of Standby Operation in CGM Devices
-
Technology4 days agoLaifen Expands U.S. Retail Footprint with Costco Launch of Best-Selling SE Hair Dryer
-
Technology5 days agoMDT Introduces TMR1370 Ultra-Low-Power Magnetic Switch IC Enabling More Than Two Years of Standby Operation in CGM Devices
